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Abstract
Background: Kinesin spindle proteins (KSP) are motor proteins that play an essential role in
mitotic spindle formation. HsEg5, a KSP, is responsible for the formation of the bipolar spindle,
which is critical for proper cell division during mitosis. The function of HsEg5 provides a novel
target for the manipulation of the cell cycle and the induction of apoptosis. SB715992, an
experimental KSP inhibitor, has been shown to perturb bipolar spindle formation, thus making it
an excellent candidate for anti-cancer agent. Our major objective was a) to investigate the cell
growth inhibitory effects of SB715992 on PC-3 human prostate cancer cell line, b) to investigate
whether the growth inhibitory effects of SB715992 could be enhanced when combined with
genistein, a naturally occurring isoflavone and, c) to determine gene expression profile to establish
molecular mechanism of action of SB715992.
Methods: PC-3 cells were treated with varying concentration of SB715992, 30 µM of genistein,
and SB715992 plus 30 µM of genistein. After treatments, PC-3 cells were assayed for cell
proliferation, induction of apoptosis, and alteration in gene and protein expression using cell
inhibition assay, apoptosis assay, microarray analysis, real-time RT-PCR, and Western Blot analysis.
Results: SB715992 inhibited cell proliferation and induced apoptosis in PC-3 cells. SB715992 was
found to regulate the expression of genes related to the control of cell proliferation, cell cycle, cell
signaling pathways, and apoptosis. In addition, our results showed that combination treatment with
SB715992 and genistein caused significantly greater cell growth inhibition and induction of
apoptosis compared to the effects of either agent alone.
Conclusion: Our results clearly show that SB715992 is a potent anti-tumor agent whose
therapeutic effects could be enhanced by genistein. Hence, we believe that SB715992 could be a
novel agent for the treatment of prostate cancer with greater success when combined with a nontoxic natural agent like genistein.
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Background
Prostate cancer is one of the leading causes of cancer fatality in the United States amongst males [1]. Development
of chemotherapeutic agents to induce apoptosis of tumor
cells with lower toxicity in patients is currently being
investigated by many scientists. Many of these agents have
been synthetically engineered or derived from natural
plant products. Genistein, a predominant soy isoflavone,
has been shown to inhibit proliferation in tumor cells in
vitro and in vivo without any visible toxicity to normal cells
[2,3]. In addition, individuals with diets high in soy show
considerably lower incidences of prostate cancer [4]. At
the molecular level, genistein is known as a protein tyrosine kinase inhibitor and has been shown to alter the
expression of genes, which are critical for the control of
cell proliferation, apoptosis, and cell signalling [5]. Tyrosine kinase is involved in many multi-cellular aspects of an
organism [6]. In prostate epithelial cells, tyrosine kinase
regulates cell-to-cell signaling that regulates growth, differentiation, adhesion, motility and programmed cell death,
which ultimately play significant roles in the manifestation of human disease states such as diabetes and cancer
[6]. With this information at hand, we studied the growth
inhibitory effects of genistein with a new experimental
anti-mitotic agent SB715992, chemically defined as n-(3amino-propyl)-n- [R-1-(3-benzyl-7-chloro-4-oxo-3, 4-dihydroquinazolin-2-yl)-2-methyl-propyl]-4-methyl-benzanide methanesulfonate (C30H33ClN4O2CH4O3S).
SB715992 is a kinesin spindle protein (KSP) inhibitor
whose cellular effects may provide a novel treatment for
cancer. Human KSP, encoded by HsEg5, has been shown
to localize along interpolar spindle microtubules and at
the spindle poles. KSP plays a rigid role in cell mitosis and
is required for cell cycle progression. It mediates centrosome separation and formation of the bipolar mitotic
spindle, which is important for cell mitosis. Inactivation
of KSP caused improper cell division and cell cycle arrest
during mitosis, ultimately leading to apoptotic cell death
[7]. In this study, we investigated the cellular and molecular effects of SB715992 treatment alone and in combination with genistein on PC-3 human prostate cancer cells in
vitro.

Methods
Cell culture and reagents
PC-3 human prostate cancer cells (ATCC, Manassas, VA,
USA) were cultured in RPMI 1640 medium (Invitrogen,
Carlsbad, CA, USA) with 10% fetal bovine serum in a 5%
CO2 atmosphere at 37°C. Kinesin spindle protein inhibitor, SB715992, (GSK, GlaxoSmithKline, UK) was dissolved in distilled water to prepare a 1 µM stock solution.
SB715992 was then applied directly to RPMI 1640
medium in experimental cultures at varying concentration. Tyrosine kinase inhibitor, genistein (Toronto
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Research Chemicals, North York, Ontario, Canada), was
dissolved in sterile 0.1 M Na2CO3 to prepare a 10 mM
stock solution. Subsequently, genistein was also applied
directly to RPMI 1640 medium at the concentration of 30
µM in experimental cultures.
Cell inhibition assay
PC-3 prostate cancer cells were seeded in 96 well plates at
a density of 4 × 103 cells/well. PC-3 cells were incubated
for 24 hours to allow attachment to the surface of each
well of the tissue culture plate. Then, the cells were treated
with varying concentration of reagents and incubated for
1 to 3 days. First, PC-3 cells were treated with 15 and 30
nM of SB7159992, respectively. Second, PC-3 cells were
subjected to combinational treatments with 7.5 or 10 nM
of SB715992 plus 30 µM of genistein. Finally, PC-3 cells
were pre-treated with 30 µM of genistein for 24 hours followed by treatment with 15 nM of SB715992. Control
cells were treated with 0.3 mM Na2CO3 (vehicle control).
After treatment, PC3 cells were incubated at 37°C with
MTT (0.5 mg/ml, Sigma, St. Louis, MO, USA) for 2 hours
and isopropyl alcohol at room temperature for 1 hour.
The spectrophotometric absorbance of each sample was
then determined by using ULTRA Multifunctional Micro
Plate Reader (TECAN, Durham, NC, USA) at 595 nm.
Histone/DNA ELISA for detecting apoptosis
Apoptotic cell death was quantified with the use of Cell
Apoptosis ELISA Detection Kit (Roache, Palo Alto, CA,
USA). PC-3 cells were seeded in 6 well plates at a density
of 5.0 × 104/well and allowed 24 hours to adhere to the
surface of each well. Then, the cells were treated with varying concentrations of reagents as described above. After
treatment, cytoplasmic histone/DNA fragments from PC3 cells were extracted and adhered to an immobilized
anti-histone antibody plate. Thereafter, a peroxidase-conjugated anti-DNA antibody was used for detection of
adhered histone/DNA fragments. A substrate for peroxidase was then added to each well containing each experimental condition. The spectrophotometric absorbance of
each sample was then determined by using ULTRA Multifunctional Micro Plate Reader (TECAN, Durham, NC,
USA) at 405 nm.
DNA ladder analysis for detecting apoptosis
PC-3 cells were seeded in 100 mm dishes at 3.5 × 105 cells/
dish and allowed to adhere and grow for 36 hours. Following growth and attachment, PC-3 cells were treated
with 15 nM of SB715992 for 48 and 72 hours. After treatment, cellular cytoplasmic DNA was extracted using 10
mM Tris (pH 8.0), 0.5 mM EDTA, and 0.2% Triton X-100.
The lysate was then centrifuged at 4°C for 15 minutes at
13,800 × g to separate the cytoplasmic DNA fragments
from the nuclear pellet. The supernatant was then collected and treated with 15 µl of RNase and incubated at
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Table 1: Fold changes in selected genes treated with SB715992 tested by microarray analysis.

Fold Change
Accession Number

Gene Symbol

R64130
AI050866
NM_001106
NM_005118
NM_005228
BC001971
BC000125
AA994334
AV654063
NM_004464
AK027071
BG326045
U73844
S75264
AW514564
AF180474
N95363
AL039795
AK022513
AA994004
L78790
NM_003954
NM_030662
AW025150
AW450910
M57765
AW444761
NM_002031

PPBP
NODAL
ACVR2B
TNFSF15
EGFR
CDKN1B
TGFB1
BCL10
KRAS2
FGF5
TSC22
BHLHB2
ELF3
WT1
CHD2
CNOT3
CDKN1C
TARDBP
DUSP10
CDK11
ITGB2
MAP3K14
MAP2K2
MAP3K12
SYK
IL11
CDKN2B
FRK

Description
pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
nodal homolog (mouse)
activin A receptor, type IIB
tumor necrosis factor (ligand) superfamily, member 15
epidermal growth factor receptor
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
transforming growth factor, beta 1 (Camurati-Engelmann disease)
B-cell CLL/lymphoma 10
v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog
fibroblast growth factor 5
transforming growth factor beta 1 induced transcript 4
basic helix-loop-helix domain containing, class B, 2
E74-like factor 3 (ets domain transcription factor, epithelial-specific)
Wilms tumor 1
chromodomain helicase DNA binding protein 2
CCR4-NOT transcription complex, subunit 3
cyclin-dependent kinase inhibitor 1C (p57, Kip2)
TAR DNA binding protein
dual specificity phosphatase 10
cyclin-dependent kinase (CDC2-like) 11
integrin, beta 2 (antigen CD18 (p95)
mitogen-activated protein kinase kinase kinase 14
mitogen-activated protein kinase kinase 2
mitogen-activated protein kinase kinase kinase 12
spleen tyrosine kinase
interleukin 11
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)
fyn-related kinase

37°C for 1 hour. Following incubation, the supernatant
was treated with 20 µl of 20% SDS, 8 µl of proteinase K
(20 mg/ml), 25 µl of 5.0 M NaCl and allowed to incubate
at 37°C for 30 minutes. Thereafter, phenol/chloroform/
isoamyl-alcohol extraction and isopropyl alcohol precipitation were carried out. After precipitation, the DNA fragments were washed in 70% alcohol and separated
through a 1.5% agarose gel at 100 volts for 80 minutes.
After electrophoresis, running gels were stained with
ethidium bromide and visualized by ultra-violet light.
Microarray analysis for gene expression profiles
PC-3 cells were treated with 10 nM of SB715992 for 6, 24,
and 48 hours respectively. Total RNA was extracted from
each sample by the use of Trizol (Invitrogen, Carlsbad,
CA) following manufacture's protocol. The total RNA of
each sample was then purified with RNeasy Mini Kit and
RNase-free DNase Set (Qiagen, Valenica, CA) following
manufacturer's protocol. The purified RNA samples were
subject to microarray anaylsis using Human Genome
U133A Array (Affymetrix, Santa Clara, CA), which contains 54,613 human gene probes. Gene expression was
then quantified by using Microarray Suite, MicroDB™, and

6h

24 h

48 h

1.07
1.41
5.66
1.23
-1.52
1.32
-1.41
1.74
18.38
-1.32
NC
-1.15
-1.07
-1.15
-1.07
-1.52
-2.00
1.52
-1.32
8.57
-1.23
-1.15
-1.32
1.32
-1.52
1.07
1.07
4.29

1.74
5.28
6.50
4.92
-1.15
1.23
-1.23
2.46
13.00
-7.46
2.83
2.64
2.64
-1.41
3.48
-2.14
1.23
4.29
3.73
8.00
-1.32
-1.41
-1.32
-1.15
-1.52
-2.00
6.06
6.96

6.50
9.19
11.31
11.31
-2.00
3.03
-2.00
12.13
19.70
-6.06
5.28
9.19
6.96
-4.59
14.93
-4.29
6.06
10.56
8.57
128.00
-10.56
-2.64
-2.00
-2.00
-14.93
-4.59
9.19
25.99

Data Mining Tool Software (Affymetrix, Santa Clara, CA).
Clustering and annotation of the gene expression were
analyzed by using Cluster and TreeView [8], Onto-Express
[9], and GenMAPP [10].
Analysis of RNA expression by reverse transcriptionpolymerase chain reaction
To verify the alterations of gene expression at the mRNA
level, which appeared on the microarray, we chose representative genes (Table 1 and Table 2) with varying expression profiles for real-time RT-PCR analysis. PC-3 cells
were treated with 10 nM of SB715992 for 6 and 48 hours
and total RNA was isolated and purified as mentioned
above. Two micrograms of total RNA from each sample
were subjected to reverse transcription using the Superscript first strand cDNA synthesis kit (Invitrogen,
Carlsbad, CA) according to the manufacturer's protocol.
Real-time PCR reactions were then carried out in a total of
25 µL reaction mixture (2 µl of cDNA, 12.5 µl of 2× SYBR
Green PCR Master Mix, 1.5 µl of each 5 µM forward and
reverse primers, and 7.5 µl of H2O) in SmartCycler II
(Cepheid, Sunnyvale, CA). The PCR program was initiated by 10 min at 95°C before 40 thermal cycles, each of
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15 s at 95°C and 1 min at 60°C. Data were analyzed
according to the comparative Ct method and were normalized by actin expression in each sample. Melting
curves for each PCR reaction were generated to ensure the
purity of the amplification product.
Western blot analysis
PC-3 cells were seeded into 100 mm culture dishes at 3.0
× 105 cells per dish and allowed to attach overnight for 24
hours. The cells were treated with 10 nM of SB715992 for
24 and 48 hours. The cells were then lysed in 62.5 mM
Tris-HCl and 2% SDS. The protein concentrations of each
sample were measured using a BCA Protein Assay Kit
(PIERCE, Rockford IL). The cellular protein extracts were
then subjected to 10 or 14% of SDS-PAGE and transferred
to nitrocellulose membranes at 100 V for 2 hours at 4°C.
The membranes were incubated with anti-EGFR (1:500,
Santa Cruz, CA), anti-p27 (1:100, Santa Cruz, CA), and
anti-p15 (1:200, Santa Cruz, CA), and anti-β-actin
(1:10000, Sigma, MO) primary antibodies, and subsequently incubated with secondary antibodies conjugated
with peroxidase. The signal was then detected using
Chemiluminescent Detection System (PIERCE, Rockford,
IL).
Statistical analysis
For cell growth inhibition assay and apoptosis ELISA, statistical analysis was performed using t test between treated
and untreated samples or between monotreatment and
combination treatment. P values less than 0.05 indicate
statistical significance.

Results

A.
Figure
Inhibition
1
of PC-3 cell proliferation analyzed by MTT assay
A. Inhibition of PC-3 cell proliferation analyzed by MTT
assay. PC-3 cells were treated with 15 and 30 nM of
SB715992 respectively (*:P < 0.001 compared with control, n
= 12). B. Induction of apoptosis in PC-3 cells by SB715992
assayed by ELISA. PC-3 cells were treated with 15 and 30 nM
of SB715992 for 24 to 72 hours (*:P < 0.05, n = 3). C. Induction of apoptosis in PC-3 cells by SB715992, measured by
DNA-ladder analysis. PC-3 cells were treated with 15 nM of
SB715992. (Lanes 1: 100 bp DNA marker, 2: Control 48
hours, 3: Treatment 48 hours, 4: Control 72 hours, 5: Treatment 72 hours).

Inhibition of PC-3 prostate cancer cell proliferation by
SB715992
PC-3 prostate cancer cells were treated with 15 and 30 nM
of SB715992 and assayed for inhibition of cell proliferation. Results obtained from MTT analysis showed that
SB715992 had a time and dose related effect on the
growth of PC-3 cells (Figure 1a). Over the course of 72
hours, SB715992 caused an average increase in cell
growth inhibition of 48.65% at 15 nM and 52.16% at 30
nM with respect to control samples. Therefore, the results
from this experiment suggested that SB715992 is a potent
inhibitor of PC-3 cell growth in vitro. Given this information, we directed our investigation on the ability of
SB715992 to induce apoptosis in PC-3 prostate cancer
cells.
Induction of apoptosis in prostate cancer cell by SB715992
The induction of apoptosis was tested by two different
methods. First, the induction of apoptosis by SB715992
was detected by ELISA assay. The results obtained from
the ELISA assay showed an average of 1094.88% increase
in apoptosis when PC-3 cells were treated with 15 nM of
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Table 2: List of primer sequences used for RT-PCR analysis.

Genes

Forward Primer Sequence

Reverse Primer Sequence

IL11
CDK11
FRK
p15
CHD2
CNOT3
p57
ELF3
ACVR2B
TNFSF15
EGFR
p27
KRAS2
FGF

agctgagggacaaattcc
caaacggaaaactggatg
ccagctccatttgatttg
cacaatggagctagaagca
aagggactccaaggaatg
tggaacgagagaccaaaa
gaccgttcatgtagcagc
gagtcggaactgagggtt
tcgaagtagagctgtggc
ccacctattttgtgctgg
gtgctggatgatagacgc
tggtgatctcccaagcta
cagggcgaatttgtaatg
ttgtccttcctcctcctc

cacacctgggagctgtag
caggtgtccttgaatgct
ttatctgtgcctccctca
aattccattttcgaagcc
aggtttgcatttgtatgctt
aatccggtcctgcttatc
caccttgggaccagtgta
tgaggaggcaccagataa
catgcaggtatgagaggc
agatgatccacccacctt
attgttgctggttgcact
aaaactcccaagcacctc
gttcagtagggcagctca
agggttcctatcagtggc

SB715992 and 1516.70% when treated with 30 nM of
SB715992 for 72 hours (Figure 1b). As a result, SB715992
had also shown a time and dose related effect on the
increase of apoptosis, which was correlated with our
results obtained from MTT assay. Therefore, we decided to
confirm our ELISA data by performing a DNA ladder analysis. The results from the DNA ladder analysis also
showed a time related increase in apoptosis induced by
SB715992 (Figure 1c). Thus, the results from both the
ELISA assay and DNA ladder analysis showed clearly that
SB715992 was a strong inducer of apoptosis in prostate
cancer cells. As a result, the information obtained from
the assays for apoptosis and cell proliferation inhibition
prompted us to investigate the changes in gene expression
and the regulation caused by treatment of PC-3 prostate
cancer cells with SB715992.
Regulation of RNA expression by SB715992
The gene expression profile of PC-3 cells exposed to
SB715992 was accessed by microarray analysis using
Human Genome U133A Array. Of the 54,613 genes, a

PCR Product Size
104 b.p.
148 b.p.
202 b.p
153 b.p.
192 b.p.
218 b.p.
142 b.p.
286 b.p.
138 b.p.
211 b.p.
286 b.p.
189 b.p.
229 b.p.
117 b.p.

total of 120 at 6 hours, 418 at 24 hours, and 1713 at 48
hour were up-regulated after SB715992 treatment. Our
data also showed that 126 genes at 6 hours, 110 at 24
hours, and 1264 at 48 hours were down regulated. After
clustering and annotation of the gene expression, we
selected 34 genes with the most significant changes with
respect to categories such as apoptosis, cell cycle, cell proliferation, cell signaling, and protein kinase. Our results
showed an up-regulation of genes that induce apoptosis
and inhibit cell cycle progression and cell signalling
(Table 1). Our results also showed a down regulation of
genes related to cell survival, such as protein kinase,
growth factors, transcription, and translation (Table 1).
To confirm the data from microarray, we conducted RTPCR analysis on 16 of the 34 genes selected from the
microarray analysis. The results from our RT-PCR analysis
were in mutual agreement with the results obtained from
the microarray analysis (Table 3). The data obtained from
both RT-PCR and microarray analysis showed clearly that
SB715992 up regulated genes that are responsible for
apoptosis and cell cycle arrest, and down regulated genes

Table 3: Comparative gene expression levels from microarray and RT-PCR analysis

Gene
IL-11
CDK11
FRK
p15
CHD2
CNOT
p57
ELF3
ACVR
TNFSF
EGFR
p27
KRAS2
FGF

Description
interleukin 11
cyclin-dependent kinase (CDC2-like) 11
fyn-related kinase
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)
chromodomain helicase DNA binding protein 2
CCR4-NOT transcription complex, subunit 3
cyclin-dependent kinase inhibitor 1C (p57, Kip2)
E74-like factor 3 (ets domain transcription factor)
activin A receptor, type IIB
tumor necrosis factor (ligand) superfamily, member 15
epidermal growth factor receptor
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog
fibroblast growth factor

Microarray 48 h Fold Change

RT-PCR 48 h Fold Change

-4.59
128.00
25.99
9.19
14.93
-4.29
6.06
6.96
11.31
11.31
2.00
3.03
19.7
-6.06

-2.13
4.03
11.00
5.41
15.74
-5.01
35.84
24.53
2.95
30.00
6.00
10.90
3.56
-5.26
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EGFR after 48 hours of SB715992 (Figure 2a), suggesting
a down regulation of EGFR gene. Our results also showed
a qualitative increase in the expression of p27 (CDKN2B)
and p15 (CDKN1B) (Figure 2b and 2c), suggesting an upregulation of these genes. These results were in direct
agreement with the results obtained from microarray
analysis and RT-PCR analysis. Therefore, our results
obtained by different assays clearly suggest that SB715992
regulates the expression of genes that are vital for cell proliferation and apoptosis. Because we previously found
that genistein also regulated the expression of genes that
are critical for the control of cell growth and apoptosis, we
investigated whether combination treatment with genistein and SB715992 could exert more inhibitory effects on
PC-3 prostate cancer cell growth and induce greater degree
of apoptotic cell death compared to either agent alone.

Figure 2 and
Alteration
SB715992
in protein
analyzed
expression
by Western
in PC-3
Blot cells
analysis
treated with
Alteration in protein expression in PC-3 cells treated with
SB715992 and analyzed by Western Blot analysis. PC-3 cells
were treated with 10 nM of SB715992 (A. p27/β-actin; B.
p15/β-actin; C. IL-11/β-actin; D. EGFR/β-actin;).

that are responsible for cell proliferation and survival. As
a result, alterations in RNA expression of PC-3 cell by
SB715992 led us to investigate the alteration in protein
expression of selected critical genes, which are expressed
in prostate cancer cells and are important for cell cycle regulation and cell growth.
Regulation of protein expression in prostate cancer cells
by SB715992
In order to investigate the alteration in protein expression
in PC-3 cells, Western Blot analysis was conducted. Our
results showed a qualitative decrease in the expression of

Genistein increased anti-proliferation activity of SB715992
To investigate whether genistein could potentiate the
growth inhibitory effects of SB715992, PC-3 cells were
treated with a combination of SB715992 and genistein,
and assayed for inhibition of cell proliferation by MTT
analysis (Figure 3a). Our results showed an average
increase in growth inhibition of 29.83% when treated
with 7.5 nM of SB715992, and 36.99% when treated with
10 nM of SB715992 over 72 hours. However, when the
cells were treated with 7.5 nM SB715992 plus 30 µM of
genistein, we found 48.73% growth inhibition over 72
hours. Thus, combining SB715992 with genistein
increased the percentage of cell growth inhibition compared to mono-treatments. These results led us to investigate whether pre-treatment with genistein could sensitize
PC-3 cells to the growth inhibitory effects of SB715992.
We pre-treated PC-3 cells with 30 µM of genistein for 24
hours. After the pre-treatment, we exposed the cells to 15
nM of SB715992 for 24 and 72 hours. Our results showed
a greater degree of cell growth inhibition compared to
cells treated simultaneously with these agents (Figure 3a).
We subsequently tested whether genistein could increase
the apoptotic inducing effect of SB715992.
Genistein enhanced pro-apoptotic effect of SB715992
To test for induction of apoptosis, PC-3 cells were treated
with 30 µM of genistein, 7.5 nM of SB715992 with 30 µM
of genistein, and 10 nM of SB715992 with 30 µM of genistein. PC-3 cells were also treated with 10, 15, and 30 nM
of SB715992 for direct comparison (Figure 3b). Our
results showed that an average increase in apoptosis was
38.59% when treated with genistein compared to
untreated cells over the course of 72 hours. Also, we
observed a 7.44% increase in apoptosis when treated with
10 nM of SB715992 combined with 30 µM genistein with
respect to cells only treated with SB715992. These ELISA
results were correlated with those obtained by MTT analysis, suggesting that genistein not only induces cell growth
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Figure
A.
Inhibition
3
of PC-3 cell proliferation was enhanced by genistein as measured by MTT assay
A. Inhibition of PC-3 cell proliferation was enhanced by genistein as measured by MTT assay. G indicates treatment with 30
µM of genistein (*: P < 0.05 compared with SB715992 treatment alone, n = 5). B. Induction of apoptosis in PC-3 cells was
enhanced by genistein. G indicates treatment with 30 µM of genistein. (*: P < 0.05 compared with SB715992 treatment alone, n
= 3.). C. Inhibition of PC-3 cell proliferation was enhanced by pre-treatment with genistein. G indicates pre-treatment with 30
µM of genistein. (*: P < 0.05 compared with SB715992 treatment alone. n = 8).
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inhibitory activity of SB715992, but also caused induction
of apoptotic cell death.

Discussion
Cancer chemotherapeutic agents, which target spindle
and perturb mitosis, have been shown to be clinically
effective for the treatment of cancers. These agents are
clinically used mainly for deregulating one motor protein,
tubulin. However, kinesin spindle protein (KSP) is
another important motor protein, which makes up a
larger family of microtubules and forms bipolar spindle
with other motor proteins. This motor protein plays an
essential role in nuclear motility and mitotic spindle functions [7,11]. The mitotic spindle, commonly referred to as
the nuclear spindle, is composed of spindle fibers of
which some are adhered to chromosomes positioned at
centromeres. This effect is apparently involved in chromosomal movement [12,13]. The mitotic spindle is also
composed of continuous fibers that stretch and pass from
pole to pole forming a bipolar spindle. These bipolar
spindles are required for proper cell division [14,15].
Thus, it is critical that assembly of the spindles is accurate
and that they are maintained with high fidelity. Recently,
researchers have used this information to produce chemical agents to enhance cessation of the cell cycle and induce
apoptosis in mitotic cells, with their principle target being
the Homo sapiens Eg5 kinesin spindle protein (HsEg5/KSP)
[16]. If the functions of HsEg5/KSP can be reversed or
inhibited, this could prove to be a novel way to manipulate the cell cycle and cell proliferation in mitotic cells [7].
In this study, we found that SB715992, an experimental
KSP inhibitor, significantly inhibited the proliferation of
PC-3 human prostate cancer cells at nanomole concentration, suggesting that this inhibitor of KSP may be a potent
agent for the treatment of prostate cancer.
Current literature has shown that inhibition of KSP perturbs mitosis and leads to cell death [7,16-20]. The inhibition of KSP influences the formation of bipolar spindle
that is required for proper separation and lining of the
chromosomes during mitosis. This abnormality in chromosomes leads to programmed cell death in mitotic cells
[21]. Here, we showed that SB715992 significantly
induced apoptotic cell death in PC-3 prostate cancer cells,
suggesting that SB715992 could inhibit the formation of
bipolar spindle during cell mitosis, resulting in apoptotic
cell death of PC-3 cells.
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progression of prostate cancers. It has been well known
that cyclins associate with cyclin-dependent protein
kinases (CDKs) and CDK inhibitors to control the process
of cell cycle. The CDK inhibitors such as p27KIP1, p15, and
p57Kip2 have been demonstrated to arrest the cell cycle and
inhibit the growth of cancer cells. From gene expression
profiles, we found that SB715992 increased the expression of several cyclin-dependent kinase inhibitors including p27KIP1, p15, and p57Kip2, suggesting a positive change
in promotion of cyclin-dependent kinase inhibitors,
which could ultimately lead to cell cycle arrest (Fig. 4)
[23,24]. On the other hand, SB715992 decreased the
expression of genes such as fibroblast growth factor (FGF)
and epidermal growth factor (EGFR) and these genes are
important molecules in favour of cell survival and proliferation. Therefore decrease in the expression of these
genes could negatively regulate cell cycle progression (Fig.
4), cell proliferation, angiogenesis, motility, metastasis,
and cell signaling [22].
Another objective in this study was to investigate whether
genistein, a naturally occurring isoflavone, could potentiate the effects of SB715992 on human prostate cancer
cells. Previously, genistein has been shown to inhibit
nuclear transcription factor, NF-κB and Akt signaling
pathways in cancer cells, leading to apoptosis [21,25-29].
Genistein has also been shown to inhibit angiogenesis
and topoisomerase I & II. Our study showed that genistein
increased the growth inhibitory effects of SB715592 on
PC-3 cells. In addition, we also found that genistein could
also enhance the induction of apoptosis in PC-3 cells
induced by SB715992, suggesting that genistein could be
clinically useful when combined with SB715992. Therefore, we believe that SB715992 could be used as a novel
therapeutic agent for prostate cancer and that the pretreatment of patients with genistein prior to administration of SB715992 could even be a better therapeutic strategy with lowering systemic toxicity caused by SB715992.
However, further in-depth investigations including in vivo
study are needed in order to establish cause and effect
relationships between these altered genes and treatment
outcome in animal models as well as in human patients.
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